Avenacy to Attend J.P. Morgan 43rd Annual Healthcare Conference

SCHAUMBURG, Ill.--(BUSINESS WIRE)-- Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced that it will be attending the 43rd Annual J.P. Morgan Healthcare Conference from January 13-16, 2025 in San Francisco, CA.

At the conference, Jeff Yordon, Co-Founder & CEO, Joe Mase, Chief Operating Officer, and Peter Jensen, Vice President of Finance, will be meeting with investors, showcasing the Company’s recent accomplishments, and sharing the management team’s strategic plans moving forward. Those wishing to schedule a meeting are encouraged to contact FTI Capital Advisors at [email protected].

About Avenacy

Avenacy is a U.S.-based specialty pharmaceutical company focused on supplying critical injectable medications used to treat patients in various medically supervised settings, from acute care hospitals to outpatient clinics and physician offices. Through a rigorous and optimized selection process, the Company is building out a pipeline of high-quality FDA approved injectable products in order to ensure a resilient portfolio that can meet the needs of today’s dynamic drug supply chain. With an experienced team, commitment to quality and reliability, and product offerings intended to facilitate safe and efficient patient care, Avenacy strives to be a trusted partner for essential medications.

Avenacy was launched in 2023 and is headquartered in Schaumburg, IL. For more information, please visit http://www.avenacy.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241216944077/en/

Media
FTI Consulting
[email protected]

Source: Avenacy

You May Also Be Interested In

• Rio Tinto celebrates 60 years in Western Australia
• Lerøy Seafood Group ASA: Primary Insider Transaction
• Simply Solventless Provides Update on Filing of 2025 Annual Financial Statements and Related Management's Discussion and Analysis and Management Cease Trade Order